Kashiv signs deal with CRISTÁLIA for Xolair biosimilar in LATAM
Kashiv BioSciences has entered a partnership with Brazilian biopharmaceutical firm CRISTÁLIA to facilitate the marketing of ADL-018/Omalizumab, a proposed biosimilar…
All articles by Gullapalli Prasanna
Gullapalli Prasanna
-
-
GTCR to acquire generic drug maker Zentiva
Czech producer of generic medications Zentiva is poised for a change in ownership as Advent has agreed to sell the…
-
Kriya gains $320m in Series D for gene therapy development
Kriya Therapeutics has closed an oversubscribed Series D funding round, raising $320m, aimed at propelling its gene therapy pipeline targeting…
-
Sanofi’s Tzield gains approval in China for T1D management
China’s National Medical Products Administration (NMPA) has approved Sanofi’s Tzield (teplizumab), making it the first disease-modifying therapy for autoimmune type…
-
Kytopen and BlueWhale Bio partner for cell therapy innovation
Kytopen, a provider of continuous flow cellular engineering technologies, has collaborated with BlueWhale Bio to advance the manufacturing process of…
-
Health Canada approves Medison and Ipsen’s Bylvay to treat ALGS
Health Canada has approved Medison Pharma and Ipsen’s Bylvay (odevixibat) to treat cholestatic pruritus in patients aged 12 months and…
-
Servier to acquire potential Fragile X syndrome treatment from Kaerus
Servier has agreed to acquire Medicxi company Kaerus Bioscience's potential Fragile X syndrome (FXS) treatment, KER-0193. Servier will pay Kaerus…
-
Epigenic raises $60m for epigenetic treatment development
China’s Epigenic Therapeutics has completed a Series B funding round, raising $60m to support the clinical development of its epigenetic…
-
MD Anderson and Phoenix to advance cell and gene therapy tech
The University of Texas MD Anderson Cancer Center in the US and Phoenix SENOLYTIX have announced a worldwide cross-licensing agreement…
-
Hengrui Pharma signs deal with Braveheart Bio for HRS-1893
Hengrui Pharma has agreed with US-based Braveheart Bio, which specialises in cardiovascular diseases, granting it an exclusive licence for its…